Ketaki Gokhale
Bloomberg
India
Contact Ketaki
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Ketaki:
Drug Prices to Drop Regardless of U.S. Vote Outcome, Witty Says
Pressure on drug prices in the U.S. will continue regardless of who wins the presidency, the chief executive of the U.K.’s biggest drugmaker said. → Read More
Glaxo’s Profit Beats Estimates; Sales of New Products Surge
GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, reported third-quarter profit that beat analysts’ estimates as sales of its new HIV treatments and respiratory treatments accelerated, helped by the decline of the pound. → Read More
Glaxo Sticks to 2016 Forecast as U.S. Pricing Pressure Continues
GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, left its profit forecast unchanged even after a record drop in the pound helped third-quarter sales and earnings exceed expectations. → Read More
Glaxo Seeks FDA Approval for Experimental Shingles Vaccine
GlaxoSmithKline Plc said it sought regulatory approval in the U.S. for its experimental shingles vaccine which, if successful, could generate more than $700 million in annual sales for the British drugmaker and compete with Merck & Co.’s Zostavax → Read More
Glaxo, Alphabet Form Venture to Make Bioelectronic Medicines
GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, is forming a joint venture with Google parent Alphabet Inc.’s life-sciences business to explore using electrical signals to treat diseases. → Read More
Sanofi, Boehringer Ingelheim Agree to $25 Billion Asset Swap
Sanofi agreed to a 22.8 billion-euro ($25.1 billion) asset swap with Germany’s Boehringer Ingelheim GmbH that will bolster the French drugmaker’s business in selling over-the-counter drugs. → Read More
Bayer’s Top Managers Swoop in to Buy Stock Amid Monsanto Slump
Bayer AG’s Chief Executive Officer Werner Baumann and his top lieutenants took advantage of the rout in the stock to buy 1.7 million euros ($1.9 million) of shares, signaling their confidence in the German company amid its efforts to buy Monsanto Co. → Read More
Behind the World’s Top Drugmakers’ Approach to Zika Vaccine
What if a drugmaker spent billions of dollars to create a vaccine -- only to find out humans developed natural resistance to the disease before its product is ready? → Read More
AstraZeneca Profit Falls as Recent Purchases Push Up Costs
AstraZeneca Plc said first-quarter earnings fell 12 percent as its best-selling treatments faced generic competition and costs rose following acquisitions. → Read More
Glaxo Profit Rises for First Time Since 2013, Tops Estimates
GlaxoSmithKline Plc reported its first increase in quarterly profit since 2013, as demand for its new drugs and HIV medicines helped offset declines in the sales of its blockbuster Advair. → Read More
Allergan Weighs Return to Deals With $34 Billion From Teva Sale
The end of the health-care industry’s biggest ever merger may also be the beginning of another round of deal-making for Allergan Plc. → Read More
Brushing Twice a Day Bolsters Glaxo's Generous Dividend Policy
Teeth aren’t the only thing Sensodyne toothpaste can protect from pain and erosion. The 55-year-old product holds the promise of delivering a similar service to GlaxoSmithKline Plc’s shareholders. → Read More
AstraZeneca Profit Meets Estimates as Brilinta Sales Rise
AstraZeneca Plc, the U.K.’s second-largest drugmaker, reported fourth-quarter earnings that met analysts’ estimates as sales of its heart medicine Brilinta surged. → Read More
Glaxo Fourth-Quarter Profit Falls, Missing Analyst Estimates
GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, posted fourth-quarter earnings that missed analysts’ estimates as sales of its pharmaceutical unit declined. → Read More
The Price Keeps Falling For a Superstar Gilead Drug in India
Outsiders don’t want their daughters to marry any local boys, according to the village elders swapping stories in a tailor’s shop behind the Sikh temple, because most residents are infected with black jaundice. → Read More
Patients Get Extreme to Obtain Hepatitis Drug That's 1% the Cost Outside U.S.
This is how far one Express Scripts Holding Co. executive was willing to go to secure inexpensive versions of Gilead Sciences Inc.’s hepatitis C drug Sovaldi, unavailable to U.S. consumers under federal drug import and patent laws. His plan: Dock a cruise ship flying an Indian flag off the coast of Miami. Stock the ship with versions of Sovaldi sold in India for $83,000 less than the U.S. retail… → Read More
Access to Medicines
Not long ago, being poor in a poor land meant having little or no access to the most advanced medicines. That’s slowly changing. After pharmaceutical companies were compelled to provide discounted HIV drugs to low-income countries, it was no longer a given that the ability to pay determined who got drugs. Developing countries are asserting a right to medicines at a reasonable cost and using… → Read More
Mother’s Death Shows Bribes Buy India Worst G-20 Maternal Care
Sita Devi was in labor when her family paid the day’s first bribe. The wife of Shivvaran Pal, a subsistence farmer whom she’d married at 15, Sita worked on their land and earned a monthly wage of 1,000 rupees, about $16, cooking school lunches. By 23, she had three daughters under age 3. → Read More
Indian Labs Deleted Test Results for U.S. Drugs, Documents Show
In a lab in an Indian village during the height of monsoon season in 2011, a technician hit a delete button -- a keystroke that would have consequences three years later. → Read More
Wed for Wombs, Polio Wives Show India Fails Its Weakest
From a distance, Kausalya Devi looks like most rural housewives in India -- she is squatting on the ground, bent intently over dirty vessels. → Read More